Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Future Oncol. 2019 Sep 1;15(25):2915-2931. doi: 10.2217/fon-2018-0876. Epub 2019 Feb 22.
To describe treatment patterns and outcomes for advanced/metastatic non-small-cell lung cancer (aNSCLC) treated with single-agent or combination ramucirumab (ramucirumab-based) and/or immune checkpoint inhibitor (ICI-based) therapy. Retrospective study of aNSCLC patients (n = 4054) identified in the Flatiron Health database, who received at least two treatment lines including ramucirumab- and/or ICI-based regimens between December 2014 and May 2017. Median overall survival (95% CI) from aNSCLC diagnosis was 29.3 (25.5-33.0) months for patients receiving sequential ramucirumab- and ICI-based therapy (n = 245), 15.1 (12.6-18.2) months for patients receiving sequences including ramucirumab- without ICI-based therapy (n = 112), and 23.1 (21.9-24.2) months for patients receiving ICI-based therapy without ramucirumab-based therapy in sequence (n = 3697). Results provide real-world survival estimates for aNSCLC treated with sequences including ramucirumab- and/or ICI-based therapies.
描述采用单药或联合雷莫芦单抗（雷莫芦单抗为基础）和/或免疫检查点抑制剂（ICI 为基础）治疗的晚期/转移性非小细胞肺癌（aNSCLC）的治疗模式和结局。回顾性研究了在 Flatiron Health 数据库中确定的 aNSCLC 患者（n=4054），这些患者在 2014 年 12 月至 2017 年 5 月期间接受了至少两种治疗方案，包括雷莫芦单抗和/或 ICI 为基础的方案。从 aNSCLC 诊断开始，接受序贯雷莫芦单抗和 ICI 为基础治疗的患者（n=245）的中位总生存期（95%CI）为 29.3（25.5-33.0）个月，接受包括雷莫芦单抗但无 ICI 为基础治疗的方案（n=112）的患者为 15.1（12.6-18.2）个月，接受序贯 ICI 为基础治疗但无雷莫芦单抗为基础治疗的患者（n=3697）为 23.1（21.9-24.2）个月。结果提供了接受包括雷莫芦单抗和/或 ICI 为基础治疗方案的 aNSCLC 的真实世界生存估计。
